Real-World Patient Characteristics, Utilization Patterns, and Outcomes of US Patients with HR+, HER2− Metastatic Breast Cancer Treated with Abemaciclib

BACKGROUND: Abemaciclib is the most recent oral cyclin-dependent kinase 4 and 6 inhibitor (CDK4 & 6i) to receive US Food and Drug Administration (FDA) approval to treat hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2−) advanced or metastatic breast cancer...

Descripción completa

Detalles Bibliográficos
Autores principales: Smyth, Emily Nash, Beyrer, Julie, Saverno, Kimberly R., Hadden, Elizabeth, Abedtash, Hamed, DeLuca, Angelo, Lawrence, Garreth W., Rybowski, Sarah
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2022
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9712844/
https://www.ncbi.nlm.nih.gov/pubmed/36097254
http://dx.doi.org/10.1007/s40801-022-00327-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9712844/
https://www.ncbi.nlm.nih.gov/pubmed/36097254
http://dx.doi.org/10.1007/s40801-022-00327-1

Ejemplares similares